|
|
|
|
Because physicians will be faced with deciding whether to switch from the well-established practice of recommending aspirin for use in patients with atherothrombotic disease, both aspirin and clopidogrel are compared with respect to the p rimary factors that influence such decisions (ie, their relative efficacy, safety, cost, and convenience of use). Based on the available evidence, aspirin is preferred for the majority of stroke or myocardial infarction patients at risk of recurrent athe rothrombotic events. Clopidogrel may, however, provide valuable therapeutic benefit over aspirin in patients with peripheral arterial disease and in stroke or myocardial infarction patients for whom aspirin treatment is contraindicated or for whom aspiri n fails to achieve the desired therapeutic effect. |
|